Tue, Jan 16, 2018
The company's operating costs remained at the Q2 level despite launch of a new options contract
More >
Thu, Jan 12, 2017
Piyush Nahar and Anurag Mantry analysts of Jefferies said, “We expect another muted quarter for the pharma sector led by weakness in US business. USFDA inspections and pricing in US market will continue to dominate the results. Recent comments from global peers have indicated that pricing scenario will likely remain unchanged in 2017.”
Tue, Jan 10, 2017
Prasad Koparkar, Senior Director, CRISIL Research: “Despite a favourable monsoon and lower borrowing costs, we expect key consumption-driven sectors such as automobiles, telecom services and FMCG to record the slowest growth in two years."
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
